Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Orecchia, R. | en |
dc.contributor.author | Hoekstra, H. J. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Orecchia, R. | en |
dc.creator | Hoekstra, H. J. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:28Z | |
dc.date.available | 2018-06-22T09:54:28Z | |
dc.date.issued | 2010 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42365 | |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Europe | en |
dc.subject | Article | en |
dc.subject | Female | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Chlormethine | en |
dc.subject | Cisplatin | en |
dc.subject | Cytarabine | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Neoplasms | en |
dc.subject | Patient care | en |
dc.subject | Tamoxifen | en |
dc.subject | Vinblastine | en |
dc.subject | Vincristine | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Breast neoplasms | en |
dc.subject | Mammography | en |
dc.subject | Papanicolaou test | en |
dc.subject | Computer assisted tomography | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm staging | en |
dc.subject | Priority journal | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Gemcitabine | en |
dc.subject | Navelbine | en |
dc.subject | Ondansetron | en |
dc.subject | Oxaliplatin | en |
dc.subject | Treatment outcome | en |
dc.subject | Cancer staging | en |
dc.subject | Neoplastic | en |
dc.subject | Pregnancy complications | en |
dc.subject | Fertility | en |
dc.subject | Pregnancy | en |
dc.subject | Busulfan | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Chronic myeloid leukemia | en |
dc.subject | Imatinib | en |
dc.subject | Spontaneous abortion | en |
dc.subject | Teratogenicity | en |
dc.subject | Unindexed drug | en |
dc.subject | Melanoma | en |
dc.subject | Trastuzumab | en |
dc.subject | Uterine cervix cancer | en |
dc.subject | Skin neoplasms | en |
dc.subject | Risk assessment | en |
dc.subject | Vomiting | en |
dc.subject | Follow-up studies | en |
dc.subject | Lymph node dissection | en |
dc.subject | Mastectomy | en |
dc.subject | Radiotherapy | en |
dc.subject | Malignant neoplastic disease | en |
dc.subject | Nonhuman | en |
dc.subject | Cesarean section | en |
dc.subject | Nuclear magnetic resonance imaging | en |
dc.subject | Prematurity | en |
dc.subject | Thorax radiography | en |
dc.subject | Incidence | en |
dc.subject | Pemetrexed | en |
dc.subject | Bevacizumab | en |
dc.subject | Sorafenib | en |
dc.subject | Sunitinib | en |
dc.subject | Tropisetron | en |
dc.subject | Practice guideline | en |
dc.subject | Uterine cervical neoplasms | en |
dc.subject | Drug therapy | en |
dc.subject | Combined modality therapy | en |
dc.subject | Aromatase inhibitor | en |
dc.subject | Physical examination | en |
dc.subject | Medical society | en |
dc.subject | Rituximab | en |
dc.subject | Lymphoma | en |
dc.subject | Interferon | en |
dc.subject | Chlorambucil | en |
dc.subject | Adjuvant therapy | en |
dc.subject | Antiemetics | en |
dc.subject | Aspiration biopsy | en |
dc.subject | Thiotepa | en |
dc.subject | Echography | en |
dc.subject | Infertility | en |
dc.subject | Gadolinium | en |
dc.subject | Cryopreservation | en |
dc.subject | Intrauterine growth retardation | en |
dc.subject | Aminopterin | en |
dc.subject | Colposcopy | en |
dc.subject | Female fertility | en |
dc.subject | Sentinel lymph node biopsy | en |
dc.subject | Acute leukemia | en |
dc.subject | Bone marrow biopsy | en |
dc.subject | Mutagenicity | en |
dc.subject | Pregnancy termination | en |
dc.subject | Puncture | en |
dc.subject | Radical hysterectomy | en |
dc.subject | Stillbirth | en |
dc.subject | Technetium 99m | en |
dc.title | Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdq198 | |
dc.description.volume | 21 | |
dc.description.issue | SUPPL. 5 | en |
dc.description.startingpage | v266 | |
dc.description.endingpage | v273 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |